144 related articles for article (PubMed ID: 33596152)
1. An exploratory study on the association of lifestyle factors with serum etonogestrel concentrations among contraceptive implant users.
Lazorwitz A; Sheeder J; Teal S
Eur J Contracept Reprod Health Care; 2021 Aug; 26(4):323-325. PubMed ID: 33596152
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.
Lazorwitz A; Aquilante CL; Dindinger E; Harrison M; Sheeder J; Teal S
Obstet Gynecol; 2019 Oct; 134(4):807-813. PubMed ID: 31503152
[TBL] [Abstract][Full Text] [Related]
3. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A; Aquilante CL; Oreschak K; Sheeder J; Guiahi M; Teal S
Obstet Gynecol; 2019 Apr; 133(4):783-794. PubMed ID: 30870275
[TBL] [Abstract][Full Text] [Related]
4. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Aquilante CL; Sheeder J; Guiahi M; Teal S
Contraception; 2019 Jul; 100(1):37-41. PubMed ID: 30980827
[TBL] [Abstract][Full Text] [Related]
5. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Davis A; Swartz M; Guiahi M
Contraception; 2017 Jun; 95(6):571-577. PubMed ID: 28288788
[TBL] [Abstract][Full Text] [Related]
6. Comparison of plasma etonogestrel concentrations sampled from the contralateral-to-implant and ipsilateral-to-implant arms of contraceptive implant users.
Gertz AM; Bishop IJ; Simon B; Lechiile K; Badubi O; Mussa A; Westhoff CL; Morroni C
Contraception; 2020 Dec; 102(6):403-405. PubMed ID: 32858051
[TBL] [Abstract][Full Text] [Related]
7. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Seale R; Davis A; Guiahi M
Contraception; 2020 Jul; 102(1):58-60. PubMed ID: 32325076
[TBL] [Abstract][Full Text] [Related]
8. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period.
Lazorwitz A; Sheeder J; Teal S
Contraception; 2022 Apr; 108():65-68. PubMed ID: 34973207
[TBL] [Abstract][Full Text] [Related]
9. Migration of etonogestrel subcutaneous contraceptive implants: systematic review and recommendations for practice.
Guilbert É; Arguin H; Bélanger M
Eur J Contracept Reprod Health Care; 2024 Jun; 29(3):115-130. PubMed ID: 38712717
[TBL] [Abstract][Full Text] [Related]
10. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A; Pena M; Sheeder J; Teal S
Obstet Gynecol; 2022 Apr; 139(4):579-587. PubMed ID: 35594123
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
Clure C; Sheeder J; Lazorwitz A
Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
[TBL] [Abstract][Full Text] [Related]
12. A prospective pilot study to assess the impact of the etonogestrel implant on postpartum depression.
Ross CM; Hammond C; Ralph JA; Balmert LC; Wisner KL; Kiley JW
Eur J Contracept Reprod Health Care; 2021 Apr; 26(2):98-104. PubMed ID: 33164593
[TBL] [Abstract][Full Text] [Related]
13. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
14. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
15. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users.
Diamond B; Sheeder J; Lazorwitz A
Contraception; 2024 Jan; 129():110298. PubMed ID: 37802462
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
Haas DW; Cramer YS; Godfrey C; Rosenkranz SL; Aweeka F; Berzins B; Coombs R; Coughlin K; Moran LE; Gingrich D; Zorrilla CD; Baker P; Cohn SE; Scarsi KK;
Pharmacogenet Genomics; 2020 Apr; 30(3):45-53. PubMed ID: 32106141
[TBL] [Abstract][Full Text] [Related]
17. [Two patients with a non-palpable, subcutaneously implanted contraceptive].
de Leeuw M; Oostenbroek RJ; Pijpers L; Plaisier PW
Ned Tijdschr Geneeskd; 2004 Sep; 148(36):1785-8. PubMed ID: 15495943
[TBL] [Abstract][Full Text] [Related]
18. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
19. Applicability of ancestral genotyping in pharmacogenomic research with hormonal contraception.
Lazorwitz A; Aquilante CL; Shortt JA; Sheeder J; Teal S; Gignoux CR
Clin Transl Sci; 2021 Sep; 14(5):1713-1718. PubMed ID: 33650294
[TBL] [Abstract][Full Text] [Related]
20. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
Lazorwitz A; Sheeder J; Teal S
Contraception; 2023 Jul; 123():110035. PubMed ID: 36997081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
